Randomized Adaptive Platform Trial of Pathogen-Directed Anti-inflammatory Therapy in Severe Community-Acquired Pneumonia(Core Protocal)

Launched by QINGYUAN ZHAN ·

Keywords

ClinConnect Summary

This clinical trial is studying a new way to treat severe pneumonia that people catch outside of hospitals, called severe community-acquired pneumonia (sCAP). This illness can be very serious and even life-threatening, partly because the body’s immune response can become too strong and cause damage. The study is looking at whether different doses of steroids, which are medicines that reduce inflammation, can help improve survival for patients whose pneumonia is caused by either adenovirus or a fungus called Pneumocystis jirovecii. The goal is to find the best steroid treatment to reduce the risk of death within 28 days of illness.

The trial is open to adults aged 65 to 74 who are admitted to the intensive care unit (ICU) with confirmed pneumonia caused by one of these two pathogens. Participants will be randomly assigned to receive either standard care or one of two different doses of steroids. The study uses a special design that adjusts as it goes along, so more patients are given treatments that seem to work better. This trial also helps build a research system that can quickly test new treatments if other infections causing severe pneumonia emerge in the future. Participants can expect careful monitoring during their ICU stay, and their progress will be followed closely to see how well the treatments work.

Gender

ALL

Eligibility criteria